Osteoporosis is a major and growing health concern in the Asia-Pacific region, y et it remains widely underdiagnosed and undertreated due to limited access to dual-energy X-ray absorptiometry (DXA) in many areas. Artificial intelligence (AI) offers new opportunities to improve osteoporosis screening and management, but unvalidated tools pose risks of inconsistent care. This consensus was developed to provide regionally harmonized guidance on the safe, effective, and equitable use of AI in osteoporosis care. Purpose The aim of this work was to establish expert consensus recommendations on the role of AI in osteoporosis screening and management in the Asia-Pacific region. Key objectives were to define appropriate applications of AI (e.g., imaging-based bone assessment and fracture risk prediction) and specify minimum standards for validation and reporting, addressing region-specific implementation challenges and ensuring that AI use aligns with clinical guidelines and ethical principles. Methods This consensus was developed through multidisciplinary collaboration among experts across the Asia-Pacific region. Each participant reviewed draft statements, contributed feedback during virtual meetings, and provided insights based on clinical experience and current evidence. Consensus was reached iteratively until full agreement was achieved for all statements. The process integrated global best practices and regional adaptations, drawing from peer-reviewed studies, international AI guidelines, and local fracture registry data. The final recommendations emphasize the validation, transparency, and ethical implementation of AI within regional healthcare systems, ensuring compatibility with local regulations. Ultimately, twelve consensus statements were established to guide the responsible use of AI for osteoporosis screening and management in the Asia-Pacific region. Results The panel produced 12 consensus statements covering the role of AI as an adjunct for opportunistic osteoporosis screening rather than a diagnostic tool, requirements for imaging quality and AI model transparency, standards for validation and performance reporting, integration of AI with clinical risk stratification, demonstration of clinical utility in real-world settings, adherence to data protection laws and ethical AI principles, training of clinicians in AI use, strategies for implementation and monitoring (including post-market surveillance and feedback loops), and recognition of technical, clinical, and equity limitations of AI. All 12 statements give extensive recommendations for using AI to improve osteoporosis management while ensuring patient safety, accuracy, and equity. Conclusion This first Asia-Pacific consensus on AI in osteoporosis concludes that AI, when appropriately validated and implemented, can help bridge the osteoporosis care gap by identifying high-risk patients who would otherwise remain undiagnosed, thus facilitating earlier intervention. It emphasizes that AI should complement-not replace-standard diagnostic methods and clinical judgment. The guidance emphasizes validation, transparency, and ethical oversight to facilitate early intervention while minimizing risks associated with unvalidated or premature AI adoption.
Clinical evidence on whether acute cholangitis accelerates early stent failure via rapid bacterial adhesion and biofilm formation remains limited. We assessed the influence of pre-endoscopic retrograde cholangiopancreatography (ERCP) cholangitis on time to recurrent biliary obstruction (TRBO) and early post-ERCP infection in patients with distal malignant biliary obstruction (DMBO). We retrospectively reviewed consecutive patients with DMBO who underwent their first ERCP-guided stenting at five Japanese centers (January 2020–August 2024). Patients were classified by pre-ERCP cholangitis status and matched at a 2:1 ratio of noncholangitis to cholangitis using propensity scores (PSM). The primary outcome was TRBO; secondary outcomes were post-ERCP infection, clinical success, and RBO rates. TRBO was analyzed using Kaplan–Meier, log-rank, and multivariable Cox analyses; sensitivity analyses yielded concordant results. Of 588 eligible patients, 508 had no cholangitis. PSM yielded 136 and 68 patients in well-balanced groups. The median TRBO was 140 vs. 114 d (p = 0.939). In the Cox models, nonpancreatic etiology lowered RBO risk (hazard ratio [HR]: 0.59, p = 0.04); plastic stents carried a higher risk than metal (HR: 4.71, p < 0.001), and pre-ERCP cholangitis was not associated with RBO (HR: 1.20, p = 0.46). Infections occurred in 9.6 and 4.4
BACKGROUND:Nutritional status is increasingly recognized as an important prognostic factor in chronic diseases; however, its impact on interstitial pneumonia (IP) remains unclear. The Mini Nutritional Assessment-Short Form (MNA-SF) is a practical screening tool that can be incorporated into multidisciplinary care. We evaluated the clinical usefulness of the MNA-SF score in hospitalized patients with IP. METHODS:We conducted a single-center, retrospective cohort study of consecutive patients with IP admitted between January 2022 and December 2024. Nutritional status, assessed at admission by nursing staff using the MNA-SF, was categorized as normal (score 12-14), at risk of malnutrition (8-11), or malnourished (0-7). Clinical, physiological, and radiological data were collected. Multivariable Cox proportional hazards models were used to evaluate the prognostic value of the MNA-SF. RESULTS:Among 274 patients (149 with idiopathic IP and 125 with secondary IP), 139 (50.7%) had normal nutritional status, 104 (38.0%) were at risk of malnutrition, and 31 (11.3%) were malnourished. During follow-up, 96 patients (35.4%) died. Mortality rates increased across the nutritional categories (18.7%, 44.2%, and 77.4%, respectively; p < 0.001). The MNA-SF score was significantly associated with all-cause mortality (adjusted hazard ratio, 0.90; 95% confidence interval, 0.80-0.99; p = 0.040), after adjustment for age, sex, serum C-reactive protein, percent predicted forced vital capacity, and usual interstitial pneumonia pattern on computed tomography. CONCLUSION:The MNA-SF score was significantly associated with mortality in hospitalized patients with IP. The MNA-SF may serve as a practical tool for prognostic risk stratification in hospitalized patients with IP.
Recently, we reported the real-world effectiveness of palbociclib plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC) in Japan (NCT05399329). However, median overall survival (OS) was not reached because of limited follow-up (36 months). Here, we present follow-up data from this study, including real-world clinical outcomes and treatment patterns. The P-BRIDGE study was a multi-center, observational study evaluating the real-world effectiveness and treatment patterns of patients diagnosed with HR+/HER2– ABC who received palbociclib plus ET in first (1L) or second line (2L) in Japan. The primary endpoint was real-world progression-free survival (rwPFS); secondary endpoints included OS and chemotherapy-free survival (CFS). Of the 693 eligible patients, 426 and 267 patients received palbociclib with ET as 1L and 2L treatment, respectively. After a median follow-up of 48.1 months, the median rwPFS (95
OBJECTIVE:To present a case of total intestinal aganglionosis (TIA), which is the rarest form of Hirschsprung disease (HD) and is difficult to diagnose prenatally owing to nonspecific prenatal ultrasound findings. CASE REPORT:In a 34-year-old primipara with a history of HD (total colonic aganglionosis), intestinal dilatation with intestinal movement like peristalsis was observed in the fetus starting at 36 weeks of gestation. By 38 weeks of gestation, the fetal abdominal circumference had increased, prompting cesarean section delivery. Prenatal ultrasound and postnatal barium enema findings suggested small intestinal obstruction, and the infant underwent laparotomy. However, HD was suspected based on the small intestinal dilatation associated with caliber changes. A full-layer biopsy from the dilated small intestine to the stomach revealed no ganglion cells, leading to a diagnosis of TIA. CONCLUSION:Prenatal ultrasonography may reveal fetal intestinal dilatation with intestinal movement like peristalsis in HD, even in the aganglionic portion.
